Dr.Meenakshi Srivastava's Colleagues at QED Therapeutics
Dr.Meenakshi Srivastava's Contact Details
HQ
650-231-4088
650-231-4088
Location
Company
QED Therapeutics
QED Therapeutics
Dr.Meenakshi Srivastava's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Dr.Meenakshi Srivastava
Dr.Meenakshi Srivastava currently works for QED Therapeutics.
Dr.Meenakshi Srivastava's role at QED Therapeutics is Medical Writer.
Dr.Meenakshi Srivastava's email address is ***@qedtx.com. To view Dr.Meenakshi Srivastava's full email address, please signup to ConnectPlex.
Dr.Meenakshi Srivastava works in the Biotechnology industry.
Dr.Meenakshi Srivastava's colleagues at QED Therapeutics are Jacob Mercer, Liz Bergan, Brett Kuenne, Vermali Rodriguez, Kathleen Guindon, Brian Boyles, Richard Jones II and others.
Dr.Meenakshi Srivastava's phone number is 650-231-4088